These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 22440324)

  • 1. Low serum leptin level is associated with zonisamide-induced weight loss in overweight female epilepsy patients.
    Kim DW; Yoo MW; Park KS
    Epilepsy Behav; 2012 Apr; 23(4):497-9. PubMed ID: 22440324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of zonisamide on weight. A clinical study in 103 patients with epilepsy.
    Wellmer J; Wellmer S; Bauer J
    Acta Neurol Scand; 2009 Apr; 119(4):233-8. PubMed ID: 19053955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of carbamazepine treatment on serum leptin levels.
    Uludag IF; Kulu U; Sener U; Kose S; Zorlu Y
    Epilepsy Res; 2009 Sep; 86(1):48-53. PubMed ID: 19473818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Open-label, long-term safety study of zonisamide administered to children and adolescents with epilepsy.
    Shinnar S; Pellock JM; Conry JA
    Eur J Paediatr Neurol; 2009 Jan; 13(1):3-9. PubMed ID: 18343174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A long-term follow-up of zonisamide monotherapy.
    Fukushima K; Seino M
    Epilepsia; 2006 Nov; 47(11):1860-4. PubMed ID: 17116025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective study of body weight and serum leptin levels in patients treated with topiramate.
    Theisen FM; Beyenburg S; Gebhardt S; Kluge M; Blum WF; Remschmidt H; Elger CE; Hebebrand J
    Clin Neuropharmacol; 2008; 31(4):226-30. PubMed ID: 18670246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of zonisamide on serum immunoglobulins.
    Fujimoto Y; Ikoma R; Shimizu T; Shimizu A
    Arzneimittelforschung; 1990 Aug; 40(8):855-8. PubMed ID: 2242076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term weight loss decreases the nontraditional cardiovascular risk factors interleukin-18 and matrix metalloproteinase-9 in obese subjects.
    Madsen EL; Bruun JM; Skogstrand K; Hougaard DM; Christiansen T; Richelsen B
    Metabolism; 2009 Jul; 58(7):946-53. PubMed ID: 19409578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of a clinically significant effect of zonisamide on phenytoin steady-state pharmacokinetics in patients with epilepsy.
    Levy RH; Ragueneau-Majlessi I; Garnett WR; Schmerler M; Rosenfeld W; Shah J; Pan WJ
    J Clin Pharmacol; 2004 Nov; 44(11):1230-4. PubMed ID: 15496640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term efficacy and safety of monotherapy and adjunctive therapy with zonisamide.
    Tosches WA; Tisdell J
    Epilepsy Behav; 2006 May; 8(3):522-6. PubMed ID: 16542880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zonisamide monotherapy for epilepsy in children and young adults.
    Wilfong AA
    Pediatr Neurol; 2005 Feb; 32(2):77-80. PubMed ID: 15664764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weight issues for people with epilepsy--a review.
    Ben-Menachem E
    Epilepsia; 2007; 48 Suppl 9():42-5. PubMed ID: 18047602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zonisamide: physician and patient experiences.
    Marmarou A; Pellock JM
    Epilepsy Res; 2005; 64(1-2):63-9. PubMed ID: 15869867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term cognitive and mood effects of zonisamide monotherapy in epilepsy patients.
    Park SP; Hwang YH; Lee HW; Suh CK; Kwon SH; Lee BI
    Epilepsy Behav; 2008 Jan; 12(1):102-8. PubMed ID: 17945539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between weight loss maintenance and changes in serum leptin levels.
    Wing RR; Sinha MK; Considine RV; Lang W; Caro JF
    Horm Metab Res; 1996 Dec; 28(12):698-703. PubMed ID: 9013745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zonisamide in children and young adults with refractory epilepsy: an open label, multicenter Italian study.
    Coppola G; Grosso S; Verrotti A; Parisi P; Luchetti A; Franzoni E; Mangano S; Pelliccia A; Operto FF; Iannetti P; Curatolo P; Balestri P; Pascotto A
    Epilepsy Res; 2009 Feb; 83(2-3):112-6. PubMed ID: 19081227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of valproic acid treatment on body composition, leptin and the soluble leptin receptor in epileptic children.
    Rauchenzauner M; Haberlandt E; Scholl-Bürgi S; Karall D; Schoenherr E; Tatarczyk T; Engl J; Laimer M; Luef G; Ebenbichler CF
    Epilepsy Res; 2008 Aug; 80(2-3):142-9. PubMed ID: 18472247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum ghrelin, leptin and adiponectin levels before and after weight loss: comparison of three methods of treatment--a prospective study.
    Kotidis EV; Koliakos GG; Baltzopoulos VG; Ioannidis KN; Yovos JG; Papavramidis ST
    Obes Surg; 2006 Nov; 16(11):1425-32. PubMed ID: 17132406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zonisamide in the management of epilepsy--Japanese experience.
    Ohtahara S
    Epilepsy Res; 2006 Feb; 68 Suppl 2():S25-33. PubMed ID: 16321507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of adjunctive therapy with zonisamide in childhood intractable epilepsy.
    Lee YJ; Kang HC; Seo JH; Lee JS; Kim HD
    Brain Dev; 2010 Mar; 32(3):208-12. PubMed ID: 19304420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.